Biome Australia Ltd
AASX:BIO0.38
AUD
+0.02
(+4.11%)
ISIN
AU0000184137
Return %
Stock
S&P 500
1Y
-19.15
14.20
3Y
204.00
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Blair William Brabin Vega Norfolk
- Full Time Employees
- 30
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 192-194 Johnston Street Collingwood VIC Australia 3066
- IPO Date
- Nov 25, 2021
- Website
- biomeaustralia.com
- Similar Companies
- Business
- Biome Australia Limited is a biotechnology company primarily engaged in the research, development, and commercialization of natural product-based pharmaceutical and cosmetic solutions. The company's core product portfolio includes the discovery and development of innovative botanical extracts and bioactive compounds for use in drug development, nutraceuticals, and cosmeceuticals. Biome Australia's offerings encompass natural health products, skin care formulations, and proprietary botanical ingredients designed to address a range of therapeutic and wellness applications. The company operates predominantly in Australia with a focus on leveraging Australia's unique biodiversity for commercial product development. Founded in 2001 and headquartered in Melbourne, Australia, Biome Australia has expanded its operational footprint through strategic partnerships and collaborative research alliances in the health and wellness sectors. In the last 1-2 years, the company has notably advanced its pipeline by launching new natural ingredient formulations and entering key partnerships to enhance its product innovation and market reach. These developments include alliances with pharmaceutical and cosmetic industry players to co-develop and license new botanical-based actives. Biome Australia has also bolstered its commercial capabilities to accelerate product launches and scale production. The company mainly serves pharmaceutical, cosmetic, and wellness markets, targeting customers seeking natural and scientifically validated product ingredients. It operates research and development laboratories and has established a network for clinical testing and regulatory compliance to support product claims. Biome Australia Limited is publicly traded on the Australian Securities Exchange under the ticker BIO.AX and continues to invest in proprietary technologies aimed at sustainable and effective natural health solutions. In sum, Biome Australia Limited is a biotechnology company focused on natural product discovery and development for pharmaceutical and cosmetic use, with a strong presence in Australia and recently expanded partnerships and product offerings designed to enhance its market presence and innovation pipeline.